8-K: Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics announced its third quarter 2024 financial results and provided a business update, highlighting progress in its development portfolio and upcoming data readouts.

Summary

• Lisata Therapeutics reported a net loss of $4.9 million for the third quarter of 2024, compared to a $5.3 million loss in the same period of 2023.
• Operating expenses decreased by 10.5% to $5.3 million, primarily due to a reduction in research and development expenses.
• Research and development expenses decreased by 24.8% to $2.5 million, mainly due to lower clinical research organization expenses.
• General and administrative expenses increased by 8.1% to $2.8 million, primarily due to higher consulting expenses.
• The company's cash, cash equivalents, and marketable securities totaled approximately $35.9 million as of September 30, 2024.
• Lisata believes its current capital will fund operations into early 2026, covering anticipated data milestones from ongoing and planned clinical trials.
• The company is advancing its certepetide development program, with multiple clinical trials underway for various solid tumors.
• Data from the Phase 2b ASCEND trial's Cohort A is expected in January 2025, with Cohort B data expected in mid-2025.
• The BOLSTER trial achieved complete enrollment in first-line cholangiocarcinoma six months ahead of schedule, with topline data expected in mid-2025.
• A second cohort has been added to the BOLSTER trial to evaluate second-line cholangiocarcinoma, with enrollment completion expected in the first half of 2025.
• The CENDIFOX trial has completed enrollment in the pancreatic cohort and expects to complete enrollment in the remaining two cohorts by the end of 2024.
• The iLSTA trial is on track to complete enrollment by the first half of 2025.
• Enrollment completion for the glioblastoma multiforme (GBM) study is expected in the second half of 2025.
• The first patient in the FORTIFIDE study is expected to be enrolled by the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong clinical progress and a solid cash position, but the company is still operating at a loss and faces risks associated with clinical development.

Positives

• The company's cash position is strong, with a projected runway into early 2026.
• Lisata has a diverse and expanding development portfolio with multiple clinical trials underway.
• Certepetide has received multiple regulatory designations, which could expedite its development and approval.
• The company has established strategic partnerships that provide additional resources and expertise.
• Lisata has a seasoned management team with a proven track record.
• The company is making progress in its clinical trials, with some enrolling faster than expected.
• Certepetide has shown promising results in preclinical and early clinical studies.

Negatives

• The company continues to operate at a loss, with a net loss of $4.9 million for the third quarter of 2024.
• General and administrative expenses increased by 8.1% in the third quarter of 2024.
• The company is still in the clinical stage and has not yet generated revenue from product sales.
• The company is dependent on the success of its clinical trials and regulatory approvals.

Risks

• Clinical trial results may not be positive, and product candidates may not demonstrate safety and efficacy in larger-scale trials.
• Regulatory authorities may delay or deny approval of the company's product candidates.
• The company may face challenges in financing its operations and may need to raise additional capital.
• The company may face competition from other pharmaceutical companies developing similar therapies.
• The company's intellectual property rights may not be adequately protected.
• The company's clinical programs may be subject to regulatory delays.

Future Outlook

The company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials.

Management Comments

• We are pleased to share the progress made in the third quarter of 2024, highlighted by the advancement of our robust development portfolio centered around our novel product candidate, certepetide, stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata.
• While we await preliminary results from Cohort A of the Phase 2b ASCEND trial expected this quarter, we continue to explore the broad application of certepetides unique mechanism of action.

Industry Context

Lisata is operating in the competitive pharmaceutical industry, focusing on developing innovative therapies for solid tumors. The company's approach of enhancing existing therapies with certepetide aligns with the industry's trend of combination therapies and targeted drug delivery. The company's focus on pancreatic cancer and other difficult-to-treat cancers addresses a significant unmet medical need.

Comparison to Industry Standards

• Lisata's focus on enhancing existing therapies with certepetide is similar to other companies exploring combination therapies, such as those combining immunotherapies with chemotherapy.
• The company's clinical trial designs, including randomized, double-blind, placebo-controlled studies, are consistent with industry standards for evaluating new drug candidates.
• The company's partnerships with academic institutions and other pharmaceutical companies are common in the industry, allowing for shared resources and expertise.
• The company's cash runway into early 2026 is a positive sign, as many biotech companies face challenges in securing funding for their operations.
• The company's focus on orphan drug designations is a common strategy for companies developing therapies for rare diseases, as it provides regulatory and financial benefits.
• The company's development of certepetide for pancreatic cancer is in line with the industry's focus on this difficult-to-treat cancer, with companies like Halozyme and Rafael Pharmaceuticals also working in this area.

Stakeholder Impact

• Shareholders will be interested in the company's financial performance and clinical trial progress.
• Employees will be impacted by the company's financial stability and growth prospects.
• Patients with solid tumors may benefit from the company's development of new therapies.
• Partners will be interested in the company's progress and potential for future collaborations.
• Creditors will be interested in the company's financial health and ability to repay debts.

Next Steps

• The company will present data from the ASCEND trial's Cohort A in January 2025.
• The company will continue enrollment in the second-line CCA cohort of the BOLSTER trial.
• The company will complete enrollment in the CENDIFOX trial by the end of 2024.
• The company will continue enrollment in the iLSTA trial.
• The company will continue enrollment in the glioblastoma multiforme (GBM) study.
• The company will enroll the first patient in the FORTIFIDE study by the first quarter of 2025.

Key Dates

Keywords

Certepetide, Pancreatic Cancer, Solid Tumors, Clinical Trials, Drug Development, Cholangiocarcinoma, Glioblastoma, Immunotherapy, Chemotherapy, Pharmaceutical